
    
      This study is being mandated by Ministry of Food and Drug Safety (MFDS) as a part of the
      Korea-Risk Management Plan (K-RMP) to assess safety in patients with relapsed or refractory
      AML with FLT3 mutation in routine clinical practice in Korea. This study collects data for 24
      months according to the purpose of this study in routine clinical practice as an
      observational study.
    
  